Targeted therapy with or without chemo and immunotherapy before surgery for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding chemotherapy and an immunotherapy drug (sintilimab) to targeted therapy (limertinib) before surgery works better than continuing targeted therapy alone. It is for people with stage II-IIIB EGFR-mutant lung cancer that can be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II, IIIA, or IIIB lung adenocarcinoma (a type of non-small cell lung cancer) that can be removed with surgery.
- Your tumor has an EGFR mutation (a specific change in the cancer cells).
- You have not had any prior treatment for lung cancer (like chemotherapy, radiation, or targeted therapy).
- You are between 18 and 75 years old.
- Your overall health is good (ECOG performance status 0 or 1, meaning you are fully active or only limited in strenuous activity).
- Your liver, kidney, and bone marrow function are adequate based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy combined with the immunotherapy drug sintilimab before surgery for people with stage IIA to IIIB non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests if taking a targeted therapy drug before surgery can help shrink tumors in people with a specific type of lung cancer called EGFR-mutated squamous cell carcinoma that can be removed with surgery. The goal is to see if this approach improves outcomes.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (sintilimab) before surgery helps people with a specific type of lung cancer (EGFR-mutant, non-small cell) that is at a stage where surgery can be considered. The goal is to improve outcomes by shrinking the tumor before the operation.
This trial tests if removing the main lung tumor followed by the targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer. It is for those who have not had prior treatment and are healthy enough for surgery.
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.